FDA 'Regrets' Panel's Lack of Expertise
Did FDA Rejection of Lorcaserin Lift Weight off Investors' Minds?
By Donna Young
Tuesday, October 26, 2010
WASHINGTON The FDA unsurprisingly rejected Arena Pharmaceuticals Inc.'s weight-loss drug lorcaserin, with the much-disputed rat data, which have been the subject of controversy over the past month, remaining at the center of the agency's concerns. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.